Phio Pharmaceuticals Corp Financials
This page shows Phio Pharmaceuticals Corp (PHIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 23 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Phio Pharmaceuticals Corp passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Phio Pharmaceuticals Corp generates $0.92 in operating cash flow (-$8.0M OCF vs -$8.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Phio Pharmaceuticals Corp's EBITDA was -$9.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 24.8% from the prior year.
Phio Pharmaceuticals Corp reported -$8.7M in net income in fiscal year 2025. This represents a decrease of 21.7% from the prior year.
Cash & Balance Sheet
Phio Pharmaceuticals Corp generated -$8.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 12.3% from the prior year.
Phio Pharmaceuticals Corp held $21.0M in cash against $0 in long-term debt as of fiscal year 2025.
Phio Pharmaceuticals Corp had 12M shares outstanding in fiscal year 2025. This represents an increase of 570.1% from the prior year.
Margins & Returns
Phio Pharmaceuticals Corp's ROE was -43.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 108.2 percentage points from the prior year.
Capital Allocation
Phio Pharmaceuticals Corp invested $4.6M in research and development in fiscal year 2025. This represents an increase of 26.8% from the prior year.
Phio Pharmaceuticals Corp invested $12K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1100.0% from the prior year.
PHIO Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $1.2M+10.0% | $1.1M+21.2% | $886K | N/A | $644K-25.6% | $866K-24.6% | $1.1M |
| SG&A Expenses | N/A | $1.3M+7.2% | $1.2M+25.3% | $986K | N/A | $946K-9.7% | $1.0M-1.2% | $1.1M |
| Operating Income | N/A | -$2.5M-8.5% | -$2.3M-23.3% | -$1.9M | N/A | -$1.6M+16.9% | -$1.9M+13.4% | -$2.2M |
| Interest Expense | N/A | N/A | N/A | -$125K | N/A | N/A | N/A | -$53K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$2.4M-10.4% | -$2.2M-22.4% | -$1.8M | N/A | -$1.5M+17.4% | -$1.8M+14.3% | -$2.2M |
| EPS (Diluted) | N/A | N/A | $-0.45-9.8% | $-0.41 | N/A | $-1.54+57.5% | $-3.62 | $-0.47 |
PHIO Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $21.5M+86.8% | $11.5M+1.8% | $11.3M-15.9% | $13.4M+134.2% | $5.7M-2.2% | $5.9M+10.7% | $5.3M-22.7% | $6.9M |
| Current Assets | $21.5M+86.9% | $11.5M+1.8% | $11.3M-15.9% | $13.4M+134.2% | $5.7M-2.2% | $5.9M+10.8% | $5.3M-22.7% | $6.8M |
| Cash & Equivalents | $21.0M+96.5% | $10.7M-0.6% | $10.8M-18.9% | $13.3M+146.7% | $5.4M-0.1% | $5.4M+14.7% | $4.7M-27.4% | $6.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.3M-19.6% | $1.7M+38.1% | $1.2M-5.0% | $1.3M+25.1% | $1.0M+10.4% | $919K-39.7% | $1.5M+21.9% | $1.2M |
| Current Liabilities | N/A | N/A | $1.2M-5.0% | $1.3M+25.1% | $1.0M+10.4% | $919K-39.7% | $1.5M+21.9% | $1.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $20.1M+104.8% | $9.8M-2.5% | $10.1M-17.1% | $12.2M+157.7% | $4.7M-4.5% | $4.9M+31.1% | $3.8M-32.7% | $5.6M |
| Retained Earnings | -$155.1M-1.6% | -$152.7M-1.6% | -$150.3M-1.5% | -$148.1M-1.2% | -$146.4M-1.1% | -$144.7M-1.1% | -$143.2M-1.3% | -$141.4M |
PHIO Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.1M+0.3% | -$2.1M+17.9% | -$2.5M-99.2% | -$1.3M+7.0% | -$1.4M+29.8% | -$2.0M-9.9% | -$1.8M+11.6% | -$2.0M |
| Capital Expenditures | $0-100.0% | $7K+133.3% | $3K+50.0% | $2K+100.0% | $1K | $0 | $0 | $0 |
| Free Cash Flow | -$2.1M+0.6% | -$2.1M+17.7% | -$2.5M-99.1% | -$1.3M+6.9% | -$1.4M+29.7% | -$2.0M-9.9% | -$1.8M+11.6% | -$2.0M |
| Investing Cash Flow | $0+100.0% | -$7K-133.3% | -$3K-50.0% | -$2K-125.0% | $8K | $0 | $0 | $0 |
| Financing Cash Flow | $12.4M+513.5% | $2.0M+4955.0% | $40K-99.6% | $9.2M+577.0% | $1.4M-48.8% | $2.6M | $0+100.0% | -$4K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PHIO Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -24.3%-2.8pp | -21.5%-6.9pp | -14.5% | N/A | -30.8%+18.1pp | -48.9%-10.5pp | -38.4% |
| Return on Assets | N/A | -20.8%-1.6pp | -19.2%-6.0pp | -13.2% | N/A | -26.0%+8.9pp | -34.9%-3.4pp | -31.4% |
| Current Ratio | N/A | N/A | 9.36-1.2 | 10.58+4.9 | 5.65-0.7 | 6.38+2.9 | 3.47-2.0 | 5.48 |
| Debt-to-Equity | 0.07-0.1 | 0.17+0.0 | 0.12+0.0 | 0.10-0.1 | 0.21+0.0 | 0.19-0.2 | 0.40+0.2 | 0.22 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Phio Pharmaceuticals Corp profitable?
No, Phio Pharmaceuticals Corp (PHIO) reported a net income of -$8.7M in fiscal year 2025.
What is Phio Pharmaceuticals Corp's EBITDA?
Phio Pharmaceuticals Corp (PHIO) had EBITDA of -$9.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Phio Pharmaceuticals Corp's return on equity (ROE)?
Phio Pharmaceuticals Corp (PHIO) has a return on equity of -43.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Phio Pharmaceuticals Corp's free cash flow?
Phio Pharmaceuticals Corp (PHIO) generated -$8.0M in free cash flow during fiscal year 2025. This represents a -12.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Phio Pharmaceuticals Corp's operating cash flow?
Phio Pharmaceuticals Corp (PHIO) generated -$8.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Phio Pharmaceuticals Corp's total assets?
Phio Pharmaceuticals Corp (PHIO) had $21.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Phio Pharmaceuticals Corp's capital expenditures?
Phio Pharmaceuticals Corp (PHIO) invested $12K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Phio Pharmaceuticals Corp spend on research and development?
Phio Pharmaceuticals Corp (PHIO) invested $4.6M in research and development during fiscal year 2025.
What is Phio Pharmaceuticals Corp's debt-to-equity ratio?
Phio Pharmaceuticals Corp (PHIO) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Phio Pharmaceuticals Corp's return on assets (ROA)?
Phio Pharmaceuticals Corp (PHIO) had a return on assets of -40.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Phio Pharmaceuticals Corp's cash runway?
Based on fiscal year 2025 data, Phio Pharmaceuticals Corp (PHIO) had $21.0M in cash against an annual operating cash burn of $8.0M. This gives an estimated cash runway of approximately 32 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Phio Pharmaceuticals Corp's Piotroski F-Score?
Phio Pharmaceuticals Corp (PHIO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Phio Pharmaceuticals Corp's earnings high quality?
Phio Pharmaceuticals Corp (PHIO) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.